Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use

• US 9,434,735 B2
• Filed: 07/13/2015
• Issued: 09/06/2016
• Est. Priority Date: 07/14/2014
• Status: Expired due to Fees

• Current Assignee: Signal Pharmaceuticals, LLC (Bristol-Myers Squibb Company)
• Original Assignee: Signal Pharmaceuticals, LLC (Bristol-Myers Squibb Company)
• Inventors: Chen, Ming J., Muslehiddinoglu, Jale, Ruchelman, Alexander, Connolly, Terrence Joseph
• Primary Examiner(s): Pagonakis, Anna
• Application Number:
  US14/797,542
• Publication Number:
  US 20160009722A1
• Time in Patent Office: 421 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: C07D 487/04 Ortho-condensed systems

Abstract

Provided herein is an amorphous form of 4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-N-methylbenzamide, compositions thereof, and methods of their use for treating or preventing a cancer, in particular solid tumors and hematological cancers as described herein.

Claims

1. An amorphous form of Compound 1, or a tautomer thereof:

2. The amorphous form of claim 1 which is anhydrous.

3. The amorphous form of claim 1 which is no less than about 95% pure with respect to other solid forms.

4. A pharmaceutical composition comprising about 0.1-5% by weight of the amorphous form of claim 1, about 50-80% by weight of polyethylene glycol (PEG), about 5-30% by weight of ethanol (EtOH) and about 15-45% by weight of saline.

5. A pharmaceutical composition comprising about 0.1 mg to about 1500 mg of the amorphous form of claim 1, in about 0.5 g to about 100 g of liquid which comprises about 1 g to about 60 g of PEG, about 1 g to about 20 g of EtOH and about 1 g to about 20 g of saline.